European Growth
Opportunity

Over the last four years, Avextra has built one of the only vertically integrated EU operations from genetic selection and cultivation to sales and distribution. By effectively and responsibly deploying capital, we’ve built valuable assets strategically across Europe and are already present in some of the biggest EU markets.

Meet Avextra: Europe’s leader in Cannabis-based medicine


Assets strategically developed across Europe

Country access
via high calibre partners

Avextra license/
infrastructure

Cultivation

Production

Our Vision: To understand and harness the therapeutic potential of the cannabis plant and thereby improve the quality of life for patients around the world.

Avextra controls the entire value chain

From genetic selection through to product innovation

Genetic Selection and Cultivation

Product Development and R&D

Production and Manufacturing

Distribution

Clinical Pipeline

GENETIC SELECTION aND CULTIVaTION

We have a 600m2 purpose-built cultivation facility on 250ha of land in Portugal to cultivate rare genetics for indication-based formulations.

Check out our state- of-the-art medical cannabis cultivation facility in Portugal in this behind-the-scenes.

PRODUCT DEVELOPMENT
aND R&D

Focused development of novel extract-based product innovations

PRODUCTION aND MaNUFaCTURING

In a 10,000m2 state-of-the-art GMP manufacturing facility in Germany and a highly qualified team with 75 years of experience in botanical extraction of plant-based medicines.

DISTRIBUTION

Our products are already present in 4 of the biggest EU markets with expansion plans in place. We have one of the largest sales team in Germany, equipped with exceptional connections.

Here you see some placeholder text to explain the picture.

CLINICaL PIPELINE

Clinical Program in place to gather product-specific data for future commercials, with 3 clinical programs starting in 2023.

We invest a third of our total budget in Research & Development

Press Releases

Avextra AG Announces Closing of Follow-On Capital Raise Supported by Existing and New Institutional Investors

Avextra AG Announces Closing of Follow-On Capital Raise Supported by Existing and New Institutional Investors

BENSHEIM, Germany, Feb. 07, 2024 (GLOBE NEWSWIRE) — Avextra AG (“Avextra” or the “Company”), a leading European vertically-integrated manufacturer and developer of pharmaceutical cannabis-based medicines (CBMs) located in Germany, is…

German Pain Association (DGS) and pharmaceutical company Avextra join forces to launch their new study OCEAN

German Pain Association (DGS) and pharmaceutical company Avextra join forces to launch their new study OCEAN

Bensheim, Germany, January 23, 2024 – Avextra AG (“Avextra” or the “Company”), a leading European vertically-integrated manufacturer and developer of pharmaceutical cannabis-based medicines (CBMs) located in Germany, is proud to…

AVEXTRA invests up to 15 million euros in the development of new medical cannabis research in partnership with IUCS-CESPU

AVEXTRA invests up to 15 million euros in the development of new medical cannabis research in partnership with IUCS-CESPU

Strategic partnership deepens Research & Development of medicinal cannabis in areas such as clinical trials, development of medical devices, and extraction methodologies.  Avextra will actively participate in the supervision of…

Avextra Unveils its Alliance for Evidence and Announces its Support of BELCANTO: A Clinical Trial for Oncology Patients

Avextra Unveils its Alliance for Evidence and Announces its Support of BELCANTO: A Clinical Trial for Oncology Patients

Bensheim, 18.10.2023 – Avextra is launching its Alliance for Evidence-based Cannabis Medicine: a platform focused on collaborating with healthcare professionals and researchers to generate real-world patient data with the aim…

Strategic
Partnerships

We are always looking to connect with those who share our vision. If you’re interested in receiving a detailed deck and discovering how you can be part of our success, please contact us today.

CONTaCT US:

EN